Your Email:
Your Password:

Welcome to the website of the National Tremor Foundation.

The NTF represents over 1 million people in the UK with Tremor

Please explore the website

The National Tremor Foundation (or NTF as we are known) is an organisation where we aim to provide help, support and advice to all those living with all forms of tremor irrespective of age.

The NTF was first brought to the UK from the USA in 1992 and in 1994 became a registered charity in its own right.

Each year the NTF holds an annual conference, subsidised by the NTF providing members and friends with the opportunity of not only meeting and spending some time together but also asking a panel of experts’ questions that help with improving quality of life.

The NTF produces a newsletter (NTF News) and this is available via post, email and our website. The NTF has developed close links with other UK voluntary organisations including the Parkinson’s Disease Society and the Neurological Alliance and also with international organisations including the European Parkinson’s Disease Association (EPDA) and the International Tremor Foundation. 

Misguided beliefs and a lack of awareness mean that many people with this condition never seek medical care though most would benefit from treatment. The NTF dedicates this site to the thousands of people in the UK whose lives are affected by tremor.


SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor

23 Oct 2014

SAGE Therapeutics (Nasdaq:SAGE) today announced dose initiation of the first patient in a single-center Phase 2a clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with essential tremor. This trial is designed to evaluate the safety, tolerability, pharmacokinetics and activity of SAGE-547 in patients with essential tremor, a neurological disorder that causes involuntary, rhythmic shaking with no known cause. The trial is being conducted under a newly accepted Investigational New Drug filing.

Sound Waves Can Heal Brain Disorders

16 Oct 2014

"Using ultrasound to make lesions in the body is not a new concept; however, it's been limited for the brain because of the contours, density and thickness of the skull," says neurologist and study investigator Binit Shah.  Shah and his colleagues' pilot study of patients with essential tremor - a common, usually benign condition of rhythmic shaking - was published in the New England Journal of Medicine last year and found that ultrasonic lesioning of part of the thalamus decreased tremor. The group is expanding the trial and launching other pilot studies to explore several symptoms of Parkinson's.

Scientific American

Murder mystery night raises over £700 for National Tremor Foundation

10 Oct 2014

The murder mystery night, held at The Anchor public house in Little Downham, raised more than £700 for the foundation, which in turn funds research into Primary Orthostatic Tremor.

Influence of common synaptic input to motor neurons on the neural drive to muscle in essential tremor

1 Oct 2014

By using novel methods for the decomposition of multichannel surface EMG, results provide the first systematic analysis of the neural drive to the muscle in essential tremor and elucidate some of its characteristics that determine the pathological tremulous muscle activity.

Boston Scientific Receives CE Mark For The Vercise(tm) DBS System For Treating Patients With Tremor

17 Sep 2014

Boston Scientific Corporation has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement disorder known as essential tremor (ET). Tremor is characterized by involuntary and rhythmic shaking, usually associated with difficulty in an activity such as writing or holding and controlling items.

Google To Use High-Tech Silverware To Reduce Hand Tremors

16 Sep 2014

Liftware, resembles a spoon with an oversized handle that contains the electronic sensors designed to significantly counteract the hand tremors that make eating meals difficult

Comparison between Essential Vocal Tremor and Dystonic Vocal Tremor Treated with Botulinum Toxin and Propranolol

2 Sep 2014

A randomized clinical trial between January 2012 and September 2013, to determine and compare the response to treatment with intramuscular botulinum toxin and oral propranolol on vocal tremors, essential and dystonic found that the dystonic and essential tremors differ in responses to treatment. The dystonic tremor responds positively to the injection of botulinum toxin into the thyroarytenoid muscle, but not to the use of oral propranolol.

Otolaryngology–Head and Neck Surgery (OTO-HNS) 

How Many People in the USA Have Essential Tremor? Deriving a Population Estimate Based on Epidemiological Data

13 Aug 2014

Essential tremor (ET) is often reported to be among the most prevalent movement disorders, yet the precise number of cases in the USA is not known. The goal of the current analyses was to use published data from epidemiological studies to derive an estimate of the number of people currently residing in the USA who have ET.  Using data from three studies, estimates of the number of ET cases (2012) ranged from 6.38 to 7.63 million (mean = 7.01 million). This corresponds to approximately 2.2% of the US population.

Tremor and Other Hyperkinetic Movements (TOHM) 

Patient-Reported Needs, Non-Motor Symptoms, and Quality of Life in Essential Tremor and Parkinson's Disease

5 Jun 2014

This is the first study to describe and compare the needs, barriers to care, and impact on quality of life of two distinct movement disorder groups. Results support the recent efforts of the field to identify interventions to address the non‐motor symptoms of movement disorders and indicate need for greater appreciation of the specific differences in symptoms and quality of life experienced across movement disorder diagnoses.

Tremor and Other Hyperkinetic Movements (TOHM) 

Genetics of essential tremor: From phenotype to genes, insights from both human and mouse studies

9 May 2014

This review highlights our current knowledge on ET from both a human population and mouse genetics perspective hoping to reconcile evidence from both fields and leading to novel clues guiding future studies. We argue that better communication between researchers of different fields is warranted to define the biological origin of ET in the hope of leading to the development of better treatments.

Science Direct

Web design by Tribiq